Loading...
Market
What percentage of uninsured patients will afford Adalimumab-adbm at $550 by Dec 31, 2024?
2
Resolution / Starting Odds
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%
Surveys and reports from healthcare organizations and official announcements from GoodRx and Boehringer Ingelheim
Story
GoodRx and Boehringer Partner to Offer Humira Biosimilar at Exclusive $550 Price
Jul 18, 2024, 11:03 AM
GoodRx and Boehringer Ingelheim have partnered to launch an exclusive affordability initiative for Adalimumab-adbm, Boehringer's biosimilar to Humira. The initiative sets the price for a two-pack of both high-concentration and low-concentration Adalimumab-adbm at $550, which represents a 92% discount from the original Humira price. This move is aimed at making the biosimilar more accessible to patients who have faced high costs for Humira. The discounted price is expected to make Adalimumab-adbm the lowest-priced version of Humira available in the market. However, questions remain about whether uninsured patients can afford it or find it in a retail pharmacy.
View original story
Similar markets
Less than 50% • 25%
50% - 60% • 25%
60% - 70% • 25%
More than 70% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Yes • 50%
No • 50%
Above $200 • 25%
$150-$200 • 25%
$100-$150 • 25%
Below $100 • 25%
Significant increase in patient access • 25%
Moderate increase in patient access • 25%
No significant change in patient access • 25%
Decrease in patient access • 25%
Decrease by more than 30% • 25%
Decrease by 10%-30% • 25%
Decrease by less than 10% • 25%
No significant change or increase • 25%
Drug A • 25%
Drug B • 25%
Drug C • 25%
Other • 25%
Increase by more than 10% • 25%
Increase by less than 10% • 25%
Decrease by less than 10% • 25%
Decrease by more than 10% • 25%
Yes • 50%
No • 50%
0-10% • 25%
10-20% • 25%
20-30% • 25%
30% or more • 25%
Less than 5,000 • 25%
5,000 to 10,000 • 25%
10,000 to 15,000 • 25%
More than 15,000 • 25%
Drug A • 25%
Drug B • 25%
Drug C • 25%
Other • 25%